logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2020 – Osimertinib improves DFS after surgery for localized NSCLC

Phase 3 ADAURA trial results offer additional treatment options for stage II-IIIA disease.